- Home
- SKYE vs USIO Comparison
SKYE vs USIO Comparison
Compare SKYE & USIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKYE | USIO |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 33.0M |
| IPO Year | 2013 | 1999 |
Fundamental Metrics
Financial Performance| Metric | SKYE | USIO |
|---|---|---|
| Price | $0.79 | $1.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $15.00 | $4.00 |
| AVG Volume (30 Days) | ★ 191.2K | 42.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,200,535.00 |
| Revenue This Year | N/A | $12.15 |
| Revenue Next Year | N/A | $8.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $0.57 | $1.03 |
| 52 Week High | $5.75 | $2.02 |
Technical Indicators
Market Signals| Indicator | SKYE | USIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 54.72 |
| Support Level | $0.68 | $1.03 |
| Resistance Level | $0.83 | $1.25 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 80.70 | 87.06 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.